Efficacy and safety of local–regional therapy combined with chemotherapy, immune checkpoint inhibitors and lenvatinib as first-line treatment in advanced intrahepatic cholangiocarcinoma: a multicenter retrospective cohort study
The combined regimen of local-regional therapy, chemotherapy, ICIs, and lenvatinib exhibited marked efficacy and a tolerable safety profile, establishing it as a viable first-line approach for advanced ICC.
Authors
- Zixiang Zhou (ORCID: https://orcid.org/0009-0008-5290-9263)
- Shuofeng Li (ORCID: https://orcid.org/0000-0002-6033-6476)
- Guanhua Yu
- Ziyu Xun
- Feng Shi (ORCID: https://orcid.org/0000-0002-0904-1648)
- Haitao Zhao (ORCID: https://orcid.org/0000-0002-3444-8044)
- Zhenyu Zhu
- Boyu Sun
- Nan Zhang (ORCID: https://orcid.org/0000-0001-7667-0615)
- Chengjie Li
- Mingjian Piao (ORCID: https://orcid.org/0009-0005-4981-5942)
- Xiaobo Yang (ORCID: https://orcid.org/0000-0001-6164-4131)
- Shanshan Wang (ORCID: https://orcid.org/0000-0001-6214-1405)
- Hu Li (ORCID: https://orcid.org/0009-0005-7147-5139)
- Mingming Wang (ORCID: https://orcid.org/0000-0001-6053-7449)
- Jiongyuan Li
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Peking Union Medical College Hospital (CN)
Publication Details
- Journal
- Cancer Immunology Immunotherapy
- Published
- 2025-05-30
- DOI
- https://doi.org/10.1007/s00262-025-04085-1
- Citations
- 4
- Primary Topic
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 8.03